An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer.

Trial Profile

An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Eribulin (Primary) ; Dexamethasone; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 25 Jan 2015 Planned End Date changed from 1 Sep 2014 to 1 May 2015 as reported by ClinicalTrials.gov
    • 14 Nov 2013 Planned end date changed from 1 Dec 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 22 Feb 2013 Planned end date changed from 1 Jan 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top